US company PCI Pharma Services (PCI) has started an expansion project at its Tredegar facility in Wales, UK.
With $12m investment, PCI is planning to expand the capacity of its drug manufacturing and development capabilities to support growth.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The project will involve doubling the capacity of the contained oral solid dosage form manufacturing facility’s large-scale granulation and fluid bed drying production.
New space will be developed for potent handling capabilities and a small-scale processing area for early-stage non-good manufacturing practices (GMP) processing and formulation.
The new space is scheduled to be completed by late 2021.
PCI Pharma Services chief scientific officer Richard Yarwood said: “Pharmaceutical and biopharmaceutical companies are innovating drug treatments today at a rapid pace and in greater volume.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“As the market continues to grow, we have seen an increasing number of clients look to us to provide manufacturing services across the spectrum of dosage forms.
“The expansion at Tredegar will double our large-scale manufacturing capacity to ensure that new and existing customers have their development and supply needs met now and in the future.”
In February, PCI Pharma Services started the expansion work for the bottling line capacity at its commercial packaging facility in Rockford.
30,000ft² facility has been expanded to produce 100 million bottles a year. It also includes four high-potent compound-capable suites and three new secondary packaging areas.
